CABENUVA is indicated as a complete regimen for the treatment of HIV-1 infection in specific individuals who meet a defined set of criteria. This long-acting injectable medication is intended to replace an existing, stable oral antiretroviral regimen rather than serving as an initial treatment.
For individuals to be considered eligible for CABENUVA, their HIV-1 infection must already be well-controlled on their current medication, and they must meet specific age, weight, and virological requirements.
Detailed Eligibility Criteria for CABENUVA
Eligibility for CABENUVA is determined by several key factors related to a person's health status and current HIV-1 treatment regimen.
The primary criteria include:
- Age and Weight:
- The individual must be an adult or an adolescent who is 12 years of age or older.
- They must also weigh at least 35 kg (approximately 77 pounds).
- HIV-1 Infection:
- CABENUVA is specifically for the treatment of HIV-1 infection.
- Virological Suppression:
- A critical requirement is that the individual must be virologically suppressed. This means that the amount of HIV-1 in their blood (viral load) is very low or undetectable.
- Specifically, their HIV-1 RNA must be less than 50 copies/mL. This confirms effective control of the virus by their current therapy.
- Current Regimen Status:
- CABENUVA is designed to replace a current antiretroviral regimen. It is not for individuals who are newly starting HIV-1 treatment.
- The individual must already be on a stable antiretroviral regimen, meaning their current treatment has been effective and consistent without significant issues.
Summary of Eligibility Requirements
For a clear overview of who qualifies for CABENUVA, refer to the following summary table:
| Criterion | Specific Requirement |
|---|---|
| Age | Adults and adolescents 12 years of age or older |
| Weight | At least 35 kg |
| Condition Treated | HIV-1 infection |
| Treatment Purpose | To replace an existing, stable antiretroviral regimen |
| Viral Load Status | Virologically suppressed (HIV-1 RNA <50 copies/mL) |
| Current Medication Use | Currently on a stable antiretroviral regimen |
CABENUVA provides an option for individuals who seek an alternative to daily oral medication, offering a long-acting injectable solution for managing HIV-1, provided their infection is already well-controlled.
